Genentech to present new data from neuroscience portfolio at ECTRIMS
Category: #health  By Pankaj Singh  Date: 2019-09-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech to present new data from neuroscience portfolio at ECTRIMS
  • The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.
     
  • The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neuromyelitis Optica Spectrum Disorder treatment.

Genentech, a biotechnology company and a subsidiary of Roche Group, reportedly announced that pivotal data from its neuroscience portfolio would be showcased in the 35th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) between September 11 and 13 in Stockholm.

The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab for the treatment of Neuromyelitis Optica Spectrum Disorder, and latest Multiple Sclerosis research, which offers insights into progression of the disease, it comprises information from Ocrevus ® study that improve the understanding about Neurofilament Light Chain levels as a capable biomarker for forecasting disability results.

Furthermore, longer-term data of over six years to be proposed continue to show constant efficacy and safety outcomes for patients who took Ocrevus treatment previously.

Chief Medical Officer and Global Product Development Head at Genentech, Sandra Horning, M.D., stated that nervous system disorders are very difficult and complex to treat, and the company has grown its commitment towards neuroscience to enhance scientific understanding and care for conditions like Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.

Horning added that data being shown at ECTRIMS also contains positive Phase III outcomes for satralizumab taken as a monotherapy, a novel approach for the treatment of Neuromyelitis Optica Spectrum Disorder, as well as novel insights utilizing biomarkers to recognize disease progression happening in multiple sclerosis. 

Horning also stated that similar to the company’s approach with Ocrevus regarding Multiple Sclerosis, aiming at B cells as the crucial driver of disease, the company aims to provide satralizumab as an effective Neuromyelitis Optica Spectrum Disorder treatment option.

 

Source credit:  https://www.gene.com/media/press-releases/14805/2019-09-03/genentech-to-present-pivotal-data-for-sa

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...

Databricks buys 8080 Labs to boost its low code/no code offerings
Databricks buys 8080 Labs to boost its low code/no code offerings
By Pankaj Singh

California-based enterprise software company- Databricks has acquired German software startup 8080 Labs that developed bamboolib- a leading GUI for the Python-based Pandas data analysis and manipulation system. The purchase of 8080 Labs makes the fi...

Google rolls out GNI Advertising Lab for news publishers in India
Google rolls out GNI Advertising Lab for news publishers in India
By Pankaj Singh

American tech giant, Google LLC has recently announced the launch of Google News Initiative (GNI) Advertising Lab program for supporting small and medium-sized news publishers that generate original and accurate news for regional and local communitie...